What is the approval status of retatrutide
Its not-so-long-ago bankruptcy casts a little doubt that we can trust this new iteration to stick around
Ascend Medical's Vision for 2026 As we look ahead to 2026, Ascend Medical is committed to advancing precision weight management by: Expanding Access to Comprehensive GLP-1 Programs: We aim to offer integrated GLP-1 care that includes medical assessment, nutritional guidance, physical activity planning, and behavioral support all under one roof
The entire formula is: Non-GMO Gluten-Free Caffeine-Free Vegan Third-party lab tested for purity and potency Disclaimer : These statements have not been evaluated by the FDA
In the Phase 2 trial, retatrutide 12 mg weekly produced mean weight loss of 24.2% at 48 weeks, with the highest-dose group achieving 28.7% at the same timepoint in the TRIUMPH-4 Phase 3 trial
Although experimental studies suggest potential pancreatic harm from GLP-1 RAs, robust clinical evidence demonstrates that these drugs do not increase the incidence of pancreatitis or pancreatic cancer in diverse human populations